Select a category to explore research frontiers
Loading categories...
Research on cancer cell-derived mediators inducing peripheral sensitization and neural invasion.
This frontier addresses how tumor-derived extracellular vesicles (exosomes and microvesicles) directly transfer pro-nociceptive molecules to sensory neurons, establishing a previously underexplored mechanism of cancer pain amplification. Understanding this paracrine communication pathway is critical for developing targeted therapies that block vesicle-mediated pain signaling.
This frontier investigates how tumors infiltrating or compressing peripheral nerves induce metabolic shifts in sensory neurons (glycolytic dependency, altered mitochondrial function) that amplify pain signaling. This metabolic-pain axis in cancer remains virtually unexplored despite metabolic changes being central to neuron survival in hostile tumor microenvironments.
This frontier examines bidirectional signaling between cancer-associated fibroblasts (CAFs) and peripheral nociceptors, including how CAF-derived factors (IL-6, TNF-α, NGF, chemokines) sensitize nociceptors and how neuropeptides from nociceptors condition CAF phenotype. This tumor stroma-neuron interaction is largely unexplored in the pain context.
This frontier focuses on how chronic nociceptive input from tumors drives maladaptive central nervous system changes (spinal cord synaptic remodeling, altered endogenous pain modulation, glial activation) that perpetuate pain even after tumor shrinkage. The mechanistic link between sustained tumor-derived nociceptive input and CNS neuroplasticity remains understudied.
This frontier examines how tumors alter the morphology, density, and distribution of sensory nerve fibers within and surrounding the tumor mass, including sprouting, retraction, and changes in small fiber versus large fiber populations. This structural remodeling of the nociceptive sensory network by tumors is largely uncharacterized.
This frontier investigates whether immune cells infiltrating tumors form functional synaptic-like contacts with nociceptors (analogous to neuroimmune synapses discovered in other tissues), enabling direct rapid pain signaling independent of diffusible mediators. This structural basis for immune-nociceptor communication in cancer pain is unexplored.
This frontier focuses on how the hypoxic tumor microenvironment directly reprograms expression and function of nociceptor ion channels (TRPV1, TRPV4, ASIC, P2X), establishing hypoxia-driven pain sensitization. The direct effects of tumor hypoxia on nociceptor molecular phenotype remain largely unexamined.
This frontier addresses the underexplored role of sex hormone signaling (estrogen, progesterone, androgen) in mediating sex differences in cancer pain susceptibility, tumor-immune-neuron interactions, and pain medication responses. Sexual dimorphism in cancer pain remains poorly characterized at mechanistic and tumor-host interaction levels.